Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency

OLDWICK, N.J., Oct. 24, 2019 -- (Healthcare Sales & Marketing Network) -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the European Medic... Biopharmaceuticals, Endocrinology, Regulatory Provention Bio, teplizumab, diabetes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news